Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.38 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr178.32M

Enterprise Valuekr55.61

Total Cash (Recent Filing)kr11.38M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.77

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding202,640,560

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-2.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low LeverageMinimal debt reduces solvency risk and interest burden, giving Alzinova greater flexibility to direct available capital toward research and development. This does not remove funding needs, but it limits financial stress from creditors as development continues.

Proprietary Alzheimer’s TechnologyA proprietary platform targeting amyloid-beta oligomers could provide differentiation from generic development programs and support future partnering interest. If clinical results validate the approach, the technology may underpin multiple disease-modifying opportunities.

Focused Disease-Modifying R&D StrategyConcentrating resources on disease-modifying Alzheimer’s immunotherapies creates a clear strategic identity and preserves the possibility of meaningful long-term product value. The focused approach may also make the platform easier for potential partners to evaluate.

Bears Say

Revenue Has Collapsed To ZeroThe absence of meaningful revenue shows that Alzinova remains dependent on development financing rather than commercial operations. Without a visible top-line recovery, future value depends heavily on successful clinical progress, partnering, or eventual product approval.

Persistent Operating LossesLarge recurring losses indicate that the current operating model cannot self-fund ongoing research. Continued deficits may constrain development choices and increase the need for external capital, especially if programs require larger clinical or regulatory investments.

Sustained Cash Burn And Funding DependencePersistent negative operating and free cash flow means Alzinova is consuming cash to sustain its pipeline. Over time, this increases dependence on equity financing, partnering proceeds, or other external funding and creates dilution or execution risk.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.38 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr178.32M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Nov 12, 2026 which is in 83 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on Aug 20, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 202,640,560 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.932%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.